Cannabis dosing and administration for sleep: a systematic review.
Study Design
- Type d'étude
- Systematic Review
- Population
- Sleep disorder patients
- Intervention
- Cannabis dosing and administration for sleep: a systematic review. None
- Comparateur
- None
- Critère de jugement principal
- Sleep quality
- Direction de l'effet
- Mixed
- Risque de biais
- Unclear
Abstract
STUDY OBJECTIVES: As cannabis is increasingly used to treat sleep disorders, we performed a systematic review to examine the effects of cannabis on sleep and to guide cannabis prescribers in their recommendations to patients, specifically focusing on dosing. METHODS: We searched EMBASE, Medline, and Web of Science and identified 4550 studies for screening. Five hundred sixty-eight studies were selected for full-text review and 31 were included for analysis. Study results were considered positive based on improvements in sleep architecture or subjective sleep quality. Bias in randomized controlled trials was assessed using Cochrane Risk of Bias tool 2.0. RESULTS: Sleep improvements were seen in 7 out of 19 randomized studies and in 7 out of 12 uncontrolled trials. There were no significant differences between the effects of tetrahydrocannabinol and cannabidiol. Cannabis showed most promise at improving sleep in patients with pain-related disorders, as compared to those with neurologic, psychiatric, or sleep disorders, and showed no significant effects on healthy participants' sleep. While subjective improvements in sleep quality were often observed, diagnostic testing showed no improvements in sleep architecture. Adverse events included headaches, sedation, and dizziness, and occurred more frequently at higher doses, though no serious adverse events were observed. CONCLUSION: High-quality evidence to support cannabis use for sleep remains limited. Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations.
En bref
Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations, and high-quality evidence to support cannabis use for sleep remains limited.
Used In Evidence Reviews
Similar Papers
Current psychiatry reports · 2017
Cannabis, Cannabinoids, and Sleep: a Review of the Literature.
Archives of internal medicine · 2007
Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials.
Pharmaceuticals (Basel, Switzerland) · 2012
Cannabidiol in humans-the quest for therapeutic targets.
Nutricion hospitalaria · 2015
NUTRITIONAL AND TOXICOLOGICAL ASPECTS OF SPIRULINA (ARTHROSPIRA).
CNS drugs · 2022
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
The Permanente journal · 2016